S2: ep15: Your Next Buyer Might Be an Algorithm. Is Your Brand Ready?

AI agents are shortlisting life science suppliers before humans get involved - brands invisible to AI are losing demand they cannot measure.Shownotes:Your next buyer might never visit your website. AI agents are already shortlisting suppliers, summarising product pages, and filtering out brands with poor machine-readable content - before any human in procurement gets involved.For life science marketers and commercial leaders who want to understand what the shift to AI-mediated discovery actually means for their brand right now.Matt Wilkinson's blog post "Your Next Buyer Might Be an Algorithm. Is Your Brand Ready?" sparked a sharp debate between Matt and Jasmine Gruia-Gray. The conversation moves from the Meta acquisition of Moltbook and OpenAI's hire of the OpenClaw engineer through share of model measurement, Generative Engine Optimisation, prompt injection risk, and the first mover argument - testing where the evidence is solid and where the hype needs qualifying.Key idea: AI agents are increasingly making shortlisting decisions before humans get involved - life science brands with no AI visibility strategy are losing demand they cannot even measure.What you will learn:What the Meta acquisition of Moltbook and OpenAI's OpenClaw hire signal about the commercial infrastructure being built for AI agentsWhat "share of model" means as a concept - and the honest measurement constraints that come with itHow Generative Engine Optimisation differs from SEO and which version is deliverable for a small marketing teamHow prompt injection works, what Microsoft Defender found in 60 days of monitoring, and where the real competitive risk sitsWhy citation compression means AI visibility has no page two - and what Strivenn's SLAS 2026 data reveals about where life science companies currently standThe first mover argument examined critically - including the risk-adjusted case for acting now even with infrastructure still years from maturityChapters:[00:42] Introduction and framing[02:45] Share of model - what it is and the measurement challenge[06:17] Attribution constraints and the agent monitoring opportunity[08:02] GEO versus SEO - overlap, divergence, and what is deliverable[10:04] Cross-functional dependencies and schema implementation reality[12:44] Prompt injection risk - competitive threat or reputational hazard?[15:35] Building authority versus near-term competitive exposure[18:32] First mover advantage - the honest version of the investment case[20:26] Citation compression and the cost of waiting[22:48] Practical next stepsKeywords: AI discoverability, life science marketing, share of model, generative engine optimisation, GEO, prompt injection, AI agents, B2AI, citation compression, agentic AI, AI recommendation visibility, life science commercial strategyIf this episode shifted how you think about AI visibility for your brand, subscribe to A Splice of Life Science Marketing for new episodes every fortnight. Read the full blog post and explore the AI Discoverability Hub for primary research, frameworks, and a practical audit at strivenn.com.